Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience

European Journal of Pediatrics

Volumn 174, Issue 6, 2015, Pages 707-714

  Kostjukovits, Svetlana ^a   Kalliokoski, Liisa ^b   Antila, Kaisu ^c   Korppi, Matti ^d  

^a Department of Pediatrics Malmi District Hospital   (Finland)

^b KAINUU CENTRAL HOSPITAL   (Finland)

^c NORTH KARELIA CENTRAL HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Anakinra; Autoinflammatory disease; Canakinumab; Etanercept; Hyper IgD syndrome; Mevalonate kinase deficiency

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; CANAKINUMAB; DEXAMETHASONE; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOGLOBULIN D; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE DISEASE; ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; CHILD; CLINICAL ARTICLE; EMERGENCY SURGERY; FEBRILE CONVULSION; FEMALE; FEVER; GENE MUTATION; GROWTH DISORDER; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IMMUNOGLOBULIN BLOOD LEVEL; IRITIS; LAPAROTOMY; LEUKOCYTE; LOOSE FECES; MOUTH ULCER; PATHOGENESIS; PERITONEUM ADHESION; PERITONITIS; PRIORITY JOURNAL; RASH; REVIEW; SCHOOL CHILD; SINGLE DRUG DOSE; TOPICAL TREATMENT; TREATMENT RESPONSE; VOMITING; YOUNG ADULT; CASE REPORT; COMPLICATION; INFANT; MEVALONATE KINASE DEFICIENCY; PRESCHOOL CHILD; SYNDROME;

ADOLESCENT; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; CHILD; CHILD, PRESCHOOL; ETANERCEPT; HUMANS; INFANT; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MEVALONATE KINASE DEFICIENCY; SYNDROME;

EID: 84929839699     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-015-2505-9     Document Type: Review

References (54)

1. Arkwright PD, McDermott MF, Houten SM, Frenkel J, Waterham HR, Aganna E et al (2002) Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 130(3):484–488
2. Bader-Meunier B, Florkin B, Sibilia J, Acquaviva C, Hachulla E, Grateau G, SOFREMIP (Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie), CRI (Club Rhumatismes et Inflammations) et al (2011) Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics 128(1):e152–e159
3. Bianco AM, Girardelli M, Vozzi D, Crovella S, Kleiner G, Marcuzzi A (2014) Mevalonate kinase deficiency and IBD: shared genetic background. Gut 63(8):1367–1368
4. Biggs C, Dedeoglu F (2014) A81: spectrum of mevalonate kinase deficiency: is colitis more common than we think? Arthritis Rheum 66(Suppl 11):S114
5. Bodar EJ, Kuijk LM, Drenth JP, van der Meer JW, Simon A, Frenkel J (2011) On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis 70(12):2155–2158
6. Breda L, Nozzi M, Di Marzio D, De Sanctis S, Gattorno M, Chiarelli F (2009) Recurrent pericarditis in hyper-IgD syndrome. Clin Exp Rheumatol 27(4):695
7. Campanilho-Marques R, Brogan PA (2014) Mevalonate kinase deficiency in two sisters with therapeutic response to anakinra: case report and review of the literature. Clin Rheumatol 33(11):1681–1684
8. Cantarini L, Vitale A, Magnotti F, Lucherini OM, Caso F, Frediani B et al (2013) Weekly oral alendronate in mevalonate kinase deficiency. Orphanet J Rare Dis 8:196
9. Cerretti DP, Kozlosky CJ, Mosley B, Nelson N, Van Ness K, Greenstreet TA et al (1992) Molecular cloning of the interleukin-1 beta converting enzyme. Science 256(5053):97–100
10. Cuisset L, Drenth JP, Simon A, Vincent MF, van der Velde VS, van der Meer JW et al (2001) Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. Eur J Hum Genet 9(4):260–266
11. Demirkaya E, Caglar MK, Waterham HR, Topaloğlu R, Ozen S (2007) A patient with hyper-IgD syndrome responding to anti-TNF treatment. Clin Rheumatol 26(10):1757–1759
12. European Medicines Agency. Ilaris, canakinumab: summary of product characteristics [online]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001109/WC500031680.pdf (Assessed 30th May 2014).
13. European Medicines Agency. Kineret, anakinra: summary of product characteristics [online]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000363/WC500042310.pdf (Assessed 30th May 2014).
14. Frenkel J, Rijkers GT, Mandey SH, Buurman SW, Houten SM, Wanders RJ et al (2002) Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 46:2794–2803
15. Galeotti C, Meinzer U, Quartier P, Rossi-Semerano L, Bader-Meunier B, Pillet P et al (2012) Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford) 51(10):1855–1859
16. Gençpınar P, Makay BB, Gattorno M, Caroli F, Ünsal E (2012) Mevalonate kinase deficiency (hyper IgD syndrome with periodic fever)—different faces with separate treatments: two cases and review of the literature. Turk J Pediatr 54(6):641–644
17. Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A et al (2012) Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 71(4):563–566
18. Haas D, Hoffmann GF (2006) Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J Rare Dis 1:13
19. Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G et al (2012) Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 157(8):533–541
20. Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y et al (2012) Long-term efficacy and safety profile of rilonacept in the treatment of cryopyrin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther 34(10):2091–2103
21. Hoffmann GF, Charpentier C, Mayatepek E, Mancini J, Leichsenring M, Gibson KM et al (1993) Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 91(5):915–921
22. Houten SM, Kuis W, Duran M, de Koning TJ, van Royen-Kerkhof A, Romeijn GJ, Frenkel J et al (1999) Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 22(2):175–177
23. Korppi M, Van Gijn ME, Antila K (2011) Hyperimmunoglobulinemia D and periodic fever syndrome in children. Review on therapy with biological drugs and case report. Acta Paediatr 100(1):21–25
24. Kraus CL, Culican SM (2009) Nummular keratopathy in a patient with hyper-IgD syndrome. Pediatr Rheumatol Online J 7:14
25. Kuijk LM, Mandey SH, Schellens I, Waterham HR, Rijkers GT, Coffer PJ et al (2008) Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1. Mol Immunol 45:2158–2165
26. Lachmann HJ, Goodman HJ, Andrews PA, Gallagher H, Marsh J, Breuer S et al (2006) AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: a report of two cases. Arthritis Rheum 54(6):2010–2014
27. Levy M, Arion A, Berrebi D, Cuisset L, Jeanne-Pasquier C, Bader-Meunier B et al (2013) Severe early-onset colitis revealing mevalonate kinase deficiency. Pediatrics 132(3):e779–e783
28. Li Cavoli G, Passantino D, Tortorici C, Bono L, Ferrantelli A, Giammarresi C et al (2012) Renal amyloidosis due to hyper-IgD syndrome. Nefrologia 32(6):865–866
29. Mandey SH, Kuijk LM, Frenkel J, Waterham HR (2006) A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum 54:3690–3695
30. Mansouri B, Richards L, Menter A (2014) Treatment of two patients with generalised pustular psoriasis with the interleukin-1β inhibitor gevokizumab. Br J Dermatol. doi:10.1111/bjd.13614
31. Marchetti F, Barbi E, Tommasini A, Oretti C, Ventura A (2004) Inefficacy of etanercept in a child with hyper-IgD syndrome and periodic fever. Clin Exp Rheumatol 22(6):791–792
32. Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417–426
33. Martinon F, Mayor A, Tschopp J (2009) The inflammasomes: guardians of the body. Annu Rev Immunol 27:229–265
34. Nevyjel M, Pontillo A, Calligaris L, Tommasini A, D’Osualdo A, Waterham HR et al (2007) Diagnostics and therapeutic insights in a severe case of mevalonate kinase deficiency. Pediatrics 119:e523–e527
35. Normand S, Massonnet B, Delwail A, Favot L, Cuisset L, Grateau G et al (2009) Specific increase in caspase-1 activity and secretion of IL-1 family cytokines: a putative link between mevalonate kinase deficiency and inflammation. Eur Cytokine Netw 20(3):101–107
36. Obici L, Manno C, Muda AO, Picco P, D’Osualdo A, Palladini G et al (2004) First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 50(9):2966–2969
37. Pappu AS, Bacon SP, Illingworth DR (2003) Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia. J Lab Clin Med 141(4):250–256
38. Pontillo A, Paoluzzi E, Crovella S (2010) The inhibition of mevalonate pathway induces upregulation of NALP3 expression: new insight in the pathogenesis of mevalonate kinase deficiency. Eur J Hum Genet 18:844–847
39. Rigante D, Ansuini V, Bertoni B, Pugliese AL, Avallone L, Federico G et al (2006) Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int 27(1):97–100
40. Santos JA, Aróstegui JI, Brito MJ, Neves C, Conde M (2014) Hyper-IgD and periodic fever syndrome: a new MVK mutation (p.R277G) associated with a severe phenotype. Gene 542(2):217–220
41. Shendi HM, Devlin LA, Edgar JD (2014) Interleukin 6 blockade for hyperimmunoglobulin D and periodic fever syndrome. J Clin Rheumatol 20(2):103–105
42. Shendi HM, Walsh D, Edgar JD (2012) Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome. Rheumatol Int 32(1):249–251
43. Siewert R, Ferber J, Horstmann RD, Specker C, Heering PJ, Timmann C (2006) Hereditary periodic fever with systemic amyloidosis: is hyper-IgD syndrome really a benign disease? Am J Kidney Dis 48(3):e41–e45
44. Simon A, Drewe E, van der Meer JW, Powell RJ, Kelley RI, Stalenhoef AF et al (2004) Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 75(5):476–483
45. Stoffels M, Jongekrijg J, Remijn T, Kok N, van der Meer JW, Simon A (2014) TLR2/TLR4-dependent exaggerated cytokine production in hyperimmunoglobulinaemia D and periodic fever syndrome. Rheumatology (Oxford) 54(2):363–368
46. Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley RI, Kastner DL (2003) Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 48(9):2645–2651
47. Ter Haar N, Lachmann H, Özen S, Woo P, Uziel Y, Modesto C, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever/Eurotraps Projects et al (2013) Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 72(5):678–685
48. Thors VS, Vastert SJ, Wulffraat N, van Royen A, Frenkel J, de Sain-van der Velden M et al (2014) Periodic fever in MVK deficiency: a patient initially diagnosed with incomplete Kawasaki disease. Pediatrics 133(2):e461–e465
49. Topaloğlu R, Ayaz NA, Waterham HR, Yüce A, Gumruk F, Sanal O (2008) Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up. Clin Rheumatol 27(10):1317–1320
50. Tricarico PM, Kleiner G, Valencic E, Campisciano G, Girardelli M, Crovella S et al (2014) Block of the mevalonate pathway triggers oxidative and inflammatory molecular mechanisms modulated by exogenous isoprenoid compounds. Int J Mol Sci 15(4):6843–6856
51. van der Hilst JC, Bodar EJ, Barron KS, Frenkel J, Drenth JP, van der Meer JW, International HIDS Study Group et al (2008) Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 87(6):301–310
52. van der Hilst JC, Drenth JP, Bodar EJ, Bijzet J, van der Meer JW, Simon A, International HIDS Study Group (2005) Serum amyloid A serum concentrations and genotype do not explain low incidence of amyloidosis in hyper-IgD syndrome. Amyloid 12(2):115–119
53. von Linstow ML, Rosenfeldt V (2014) Neonatal hepatitis as first manifestation of hyperimmunoglobulinemia D syndrome. Case Rep Pediatr 2014:936890
54. Yel S, Gunduz Z, Bastug F, Dusunsel R, Dursun I, Poyrazoglu H et al (2013) Amyloidosis in a child with hyperimmunoglobulinemia D syndrome. Iran J Kidney Dis 7(1):70–72